SEC Charges Former MiMedx Execs With Fraud
The C-suite executives allegedly improperly recognized revenue from distributors with which MiMedx had secret side arrangements.
Gilead to Invest $5B in Galapagos Partnership
The deal expands Gilead's investment in the European biotech as it seeks to add assets to its drug portfolio.
Insys Shares Dive on ‘Going Concern’ Doubts
The opioid seller's auditor expressed "substantial doubt" about its ability to continue as a going concern.
Biotech’s Moderna Poised for Market Debut
The startup's IPO would raise capital for "a new category of transformative medicines based on messenger RNA."
Roche Takes Full Control of Genomic Profiler
The $2.4 billion purchase of 44% of Foundation Medicine raises Roche's bet on the development of personalized cancer treatments and care.
MiMedx Announces Restatement, Replaces CFO
The biotech firm's stock falls 23% but its CEO says, "It is important that investors understand that our business performance remains strong."
A Young Biotech Firm’s Dilemma
Should publicly held, early stage biotechs issue more shares or partner with Big Pharma?
Sanofi Buys Hemophilia Drug Maker for $11B
The acquisition of Bioverativ boosts Sanofi's presence in the fast-growing, $10 billion market for hemophilia treatments.
Who Qualifies to Be CFO of a Tech Firm?
You don't necessarily need experience in the firm's specific niche. In many cases, other aspects of your background are more important.
Osiris Executives Accused of Accounting Fraud
Former CFOs Philip Jacoby and Gregory Law are among those charged with inflating the biotech firm's revenue to meet the CEO's aggressive targets.
Alexion to Cut 20% of Workforce, Move HQ
The drugmaker is restructuring as it tries to rebuild its drug pipeline amid investigations of its sales practices.